Latest Astellas Pharma Inc (ALPMF) Headlines
Post# of 5
Posted On: 03/08/2014 6:39:53 PM
Latest Astellas Pharma Inc (ALPMF) Headlines
Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Mar 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
PR Newswire - Mon Mar 03, 7:05AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc.
Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada
PR Newswire - Fri Feb 28, 6:00AM CST
Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America
GlobeNewswire - Fri Feb 28, 12:20AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea's right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MEDA: Year-End Report January-december 2013
Business Wire - Wed Feb 19, 1:12AM CST
Regulatory News:
Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
AVEO Oncology & Astellas Pharma Inc to terminate worldwide collaboration & license agreement for tivozanib and discontinue Phase 2 BATON study for colorectal cancer
M2 - Mon Feb 17, 6:21AM CST
Cancer therapeutics company AVEO Oncology (NasdaqGS:AVEO) said on Friday that it will end its worldwide collaboration and license agreement for the development and commercialisation of investigational agent tivozanib with Astellas Pharma Inc (TSE:4503) in August.
Announcement of Intention to Privatize and Invitation to Express Interest
PR Newswire - Thu Feb 13, 4:31AM CST
The Government of the Republic of Chad formally announces its intention to partially privatize the Société des Télécommunications du Tchad ("Groupe SOTEL Tchad") pursuant to the terms of law 004/PR/96. The Ministry of Commerce and Industry hereby invites interested parties to express interest to acquire a majority of the shares of SOTEL
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
Emesis (Vomiting) - Pipeline Review, H2 2013 Research Review
M2 - Tue Feb 11, 9:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/2br9cw/emesis_vomiting) has announced the addition of the "Emesis (Vomiting) - Pipeline Review, H2 2013" report to their offering. 'Emesis (Vomiting) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Emesis (Vomiting), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Emesis (Vomiting). Scope - A snapshot of the global therapeutic scenario for Emesis (Vomiting). - A review of the Emesis (Vomiting) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Emesis (Vomiting) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Emesis (Vomiting) Overview Therapeutics Development Pipeline Products for Emesis (Vomiting) - Overview Pipeline Products for Emesis (Vomiting) - Comparative Analysis Emesis (Vomiting) - Therapeutics under Development by Companies Emesis (Vomiting) - Therapeutics under Investigation by Universities/Institutes Emesis (Vomiting) - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Astellas Pharma Inc. Charleston Laboratories, Inc. Sparsha Pharma International Pvt. Ltd. NanoForm Therapeutics Ltd. Epiomed Therapeutics, Inc. Emesis (Vomiting) - Therapeutics Assessment Drug Profiles CL-108 - Drug Profile CLH-1-T - Drug Profile 5-HT3 Receptor Antagonist Patch - Drug Profile FK-886 - Drug Profile ETI-385 - Drug Profile TRIM-21 Targeting Antibody - Drug Profile aprepitant - Drug Profile CLBPC - Drug Profile CLFTC - Drug Profile CLHMC - Drug Profile CLOXC - Drug Profile CLHDC - Drug Profile CLH-5 - Drug Profile CLH-10 - Drug Profile List of Tables List of Figures Companies Mentioned Astellas Pharma Inc. Charleston Laboratories, Inc. Sparsha Pharma International Pvt. Ltd. NanoForm Therapeutics Ltd. Epiomed Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2b...s_vomiting About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Newport, Target, AVEO Pharmaceuticals, Astellas Pharma and Bristol-Myers Squibb highlighted as Zacks Bull and Bear of the Day
PR Newswire - Mon Feb 03, 8:30AM CST
Zacks Equity Research highlights Newport Corporation (Nasdaq:NEWP-Free Report) as the Bull of the Day and Target (NYSE:TGT-Free Report)as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAVEO Pharmaceuticals, Inc. (Nasdaq:AVEO-Free Report), Astellas Pharma, Inc. (OTC:ALPMY-Free Report) and Bristol-Myers Squibb (NYSE:BMY-Free Report).
Encouraging Preliminary Metallurgical Testwork for Oxide Heap Leaching at the South Houndé Project
PR Newswire - Thu Jan 30, 8:27AM CST
Sarama Resources Ltd. ("Sarama" or the "Company") is pleased to announce that preliminary metallurgical testing at its flagship South Houndé Project in south-west Burkina Faso has returned encouraging results, indicating potential for heap leach processing of oxide mineralisation. Sarama is conducting the testwork to establish a range of alternatives for the development of the South Houndé Project, with the heap leach concept presenting an attractive low-cost alternative.
Heart Transplantation - Pipeline Review, H2 2013 Report
M2 - Tue Jan 28, 2:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mlx4w/heart) has announced the addition of the "Heart Transplantation - Pipeline Review, H2 2013" report to their offering. 'Heart Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Heart Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Transplantation. Scope - A snapshot of the global therapeutic scenario for Heart Transplantation. - A review of the Heart Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Heart Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Merck & Co., Inc. Astellas Pharma Inc. Portola Pharmaceuticals, Inc. Viron Therapeutics, Inc. NasVax Ltd. ToleroTech Inc. For more information visit http://www.researchandmarkets.com/research/9mlx4w/heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Capacity Media Select Dominican Republic to Host Regionally Acclaimed Telecom Carrier Business Meeting
PR Newswire - Wed Jan 22, 8:00AM CST
The Dominican Republic is becoming one of the fastest-growing economies in the Caribbean and Latin America, reaping the rewards of policies facilitating more open trade and experiencing great levels of international investment. Within its dynamic and developing economy, the Dominican telecom industry is thriving and becoming one of the best-served telecommunications platforms in the Caribbean.
Venous Thromboembolism Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t9vr95/venous) has announced the addition of the "Venous Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Venous Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Venous Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Venous Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Astellas Pharma Inc. - Daiichi Sankyo Company, Limited - Pfizer Inc. - AstraZeneca PLC - Bristol-Myers Squibb Company - Eisai Co., Ltd. Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Hamilton Health Sciences - Ottawa Hospital Research Institute - Brigham and Women's Hospital - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova - Mayo Clinic - Universita degli Studi dell'Insubria - The Utrecht Institute for Pharmaceutical Sciences For more information visit http://www.researchandmarkets.com/research/t9vr95/venous
Thromboembolism Global Clinical Trials Review, H2, 2013 - Featuring 10 Leading Pharma Companies and 10 Institutions
M2 - Thu Jan 16, 10:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjjw86/thromboembolism) has announced the addition of the "Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - C. H. Boehringer Sohn AG & Co. KG - GlaxoSmithKline plc - Astellas Pharma Inc. - Pfizer Inc. - Daiichi Sankyo Company, Limited - AstraZeneca PLC - Bristol-Myers Squibb Company - The LEO Foundation Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Ottawa Hospital Research Institute - Hamilton Health Sciences - Beijing Chao Yang Hospital - University of Zurich - Brigham and Women's Hospital - Capital District Health Authority, Canada - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova For more information visit http://www.researchandmarkets.com/research/kj...boembolism
Early 2014 Advancing Companies with Expansion & New Distribution Opportunities: RiceBran, Whole Foods, Hain Celestial, DryShips and Chelsea Therapeutics
PR Newswire - Thu Jan 16, 8:05AM CST
News updates for NASDAQ companies making strides with financial results, new agreements & distribution opportunities: RiceBran Technologies (NASDAQ: RIBT), Whole Foods Market Inc. (NASDAQ: WFM), The Hain Celestial Group, Inc. (NASDAQ: HAIN), DryShips, Inc. (NASDAQ: DRYS) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP)
Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Mar 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
PR Newswire - Mon Mar 03, 7:05AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc.
Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada
PR Newswire - Fri Feb 28, 6:00AM CST
Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America
GlobeNewswire - Fri Feb 28, 12:20AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea's right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MEDA: Year-End Report January-december 2013
Business Wire - Wed Feb 19, 1:12AM CST
Regulatory News:
Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
AVEO Oncology & Astellas Pharma Inc to terminate worldwide collaboration & license agreement for tivozanib and discontinue Phase 2 BATON study for colorectal cancer
M2 - Mon Feb 17, 6:21AM CST
Cancer therapeutics company AVEO Oncology (NasdaqGS:AVEO) said on Friday that it will end its worldwide collaboration and license agreement for the development and commercialisation of investigational agent tivozanib with Astellas Pharma Inc (TSE:4503) in August.
Announcement of Intention to Privatize and Invitation to Express Interest
PR Newswire - Thu Feb 13, 4:31AM CST
The Government of the Republic of Chad formally announces its intention to partially privatize the Société des Télécommunications du Tchad ("Groupe SOTEL Tchad") pursuant to the terms of law 004/PR/96. The Ministry of Commerce and Industry hereby invites interested parties to express interest to acquire a majority of the shares of SOTEL
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
Emesis (Vomiting) - Pipeline Review, H2 2013 Research Review
M2 - Tue Feb 11, 9:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/2br9cw/emesis_vomiting) has announced the addition of the "Emesis (Vomiting) - Pipeline Review, H2 2013" report to their offering. 'Emesis (Vomiting) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Emesis (Vomiting), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Emesis (Vomiting). Scope - A snapshot of the global therapeutic scenario for Emesis (Vomiting). - A review of the Emesis (Vomiting) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Emesis (Vomiting) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Emesis (Vomiting) Overview Therapeutics Development Pipeline Products for Emesis (Vomiting) - Overview Pipeline Products for Emesis (Vomiting) - Comparative Analysis Emesis (Vomiting) - Therapeutics under Development by Companies Emesis (Vomiting) - Therapeutics under Investigation by Universities/Institutes Emesis (Vomiting) - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Astellas Pharma Inc. Charleston Laboratories, Inc. Sparsha Pharma International Pvt. Ltd. NanoForm Therapeutics Ltd. Epiomed Therapeutics, Inc. Emesis (Vomiting) - Therapeutics Assessment Drug Profiles CL-108 - Drug Profile CLH-1-T - Drug Profile 5-HT3 Receptor Antagonist Patch - Drug Profile FK-886 - Drug Profile ETI-385 - Drug Profile TRIM-21 Targeting Antibody - Drug Profile aprepitant - Drug Profile CLBPC - Drug Profile CLFTC - Drug Profile CLHMC - Drug Profile CLOXC - Drug Profile CLHDC - Drug Profile CLH-5 - Drug Profile CLH-10 - Drug Profile List of Tables List of Figures Companies Mentioned Astellas Pharma Inc. Charleston Laboratories, Inc. Sparsha Pharma International Pvt. Ltd. NanoForm Therapeutics Ltd. Epiomed Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2b...s_vomiting About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Newport, Target, AVEO Pharmaceuticals, Astellas Pharma and Bristol-Myers Squibb highlighted as Zacks Bull and Bear of the Day
PR Newswire - Mon Feb 03, 8:30AM CST
Zacks Equity Research highlights Newport Corporation (Nasdaq:NEWP-Free Report) as the Bull of the Day and Target (NYSE:TGT-Free Report)as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAVEO Pharmaceuticals, Inc. (Nasdaq:AVEO-Free Report), Astellas Pharma, Inc. (OTC:ALPMY-Free Report) and Bristol-Myers Squibb (NYSE:BMY-Free Report).
Encouraging Preliminary Metallurgical Testwork for Oxide Heap Leaching at the South Houndé Project
PR Newswire - Thu Jan 30, 8:27AM CST
Sarama Resources Ltd. ("Sarama" or the "Company") is pleased to announce that preliminary metallurgical testing at its flagship South Houndé Project in south-west Burkina Faso has returned encouraging results, indicating potential for heap leach processing of oxide mineralisation. Sarama is conducting the testwork to establish a range of alternatives for the development of the South Houndé Project, with the heap leach concept presenting an attractive low-cost alternative.
Heart Transplantation - Pipeline Review, H2 2013 Report
M2 - Tue Jan 28, 2:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mlx4w/heart) has announced the addition of the "Heart Transplantation - Pipeline Review, H2 2013" report to their offering. 'Heart Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Heart Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Transplantation. Scope - A snapshot of the global therapeutic scenario for Heart Transplantation. - A review of the Heart Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Heart Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Merck & Co., Inc. Astellas Pharma Inc. Portola Pharmaceuticals, Inc. Viron Therapeutics, Inc. NasVax Ltd. ToleroTech Inc. For more information visit http://www.researchandmarkets.com/research/9mlx4w/heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Capacity Media Select Dominican Republic to Host Regionally Acclaimed Telecom Carrier Business Meeting
PR Newswire - Wed Jan 22, 8:00AM CST
The Dominican Republic is becoming one of the fastest-growing economies in the Caribbean and Latin America, reaping the rewards of policies facilitating more open trade and experiencing great levels of international investment. Within its dynamic and developing economy, the Dominican telecom industry is thriving and becoming one of the best-served telecommunications platforms in the Caribbean.
Venous Thromboembolism Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t9vr95/venous) has announced the addition of the "Venous Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Venous Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Venous Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Venous Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Astellas Pharma Inc. - Daiichi Sankyo Company, Limited - Pfizer Inc. - AstraZeneca PLC - Bristol-Myers Squibb Company - Eisai Co., Ltd. Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Hamilton Health Sciences - Ottawa Hospital Research Institute - Brigham and Women's Hospital - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova - Mayo Clinic - Universita degli Studi dell'Insubria - The Utrecht Institute for Pharmaceutical Sciences For more information visit http://www.researchandmarkets.com/research/t9vr95/venous
Thromboembolism Global Clinical Trials Review, H2, 2013 - Featuring 10 Leading Pharma Companies and 10 Institutions
M2 - Thu Jan 16, 10:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjjw86/thromboembolism) has announced the addition of the "Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - C. H. Boehringer Sohn AG & Co. KG - GlaxoSmithKline plc - Astellas Pharma Inc. - Pfizer Inc. - Daiichi Sankyo Company, Limited - AstraZeneca PLC - Bristol-Myers Squibb Company - The LEO Foundation Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Ottawa Hospital Research Institute - Hamilton Health Sciences - Beijing Chao Yang Hospital - University of Zurich - Brigham and Women's Hospital - Capital District Health Authority, Canada - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova For more information visit http://www.researchandmarkets.com/research/kj...boembolism
Early 2014 Advancing Companies with Expansion & New Distribution Opportunities: RiceBran, Whole Foods, Hain Celestial, DryShips and Chelsea Therapeutics
PR Newswire - Thu Jan 16, 8:05AM CST
News updates for NASDAQ companies making strides with financial results, new agreements & distribution opportunities: RiceBran Technologies (NASDAQ: RIBT), Whole Foods Market Inc. (NASDAQ: WFM), The Hain Celestial Group, Inc. (NASDAQ: HAIN), DryShips, Inc. (NASDAQ: DRYS) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP)
(0)
(0)Astellas Pharma Inc (ALPMF) Stock Research Links
Scroll down for more posts ▼